[{"address1": "Jinchuang Plaza", "address2": "Building 1, Fourth Floor 4560 Jinke Road Pudong", "city": "Shanghai", "zip": "201210", "country": "China", "phone": "86 21 6163 2588", "website": "https://www.zailaboratory.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-na\u00efve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.", "fullTimeEmployees": 2175, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ying  Du Ph.D.", "age": 57, "title": "Founder, Chairperson & CEO", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1698822, "exercisedValue": 11985000, "unexercisedValue": 57389912}, {"maxAge": 1, "name": "Mr. Joshua L.  Smiley", "age": 53, "title": "President & COO", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1223640, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rafael G.  Amado M.D.", "age": 59, "title": "President and Head of Global Research & Development", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 1601060, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yajing  Chen Ph.D.", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 624562, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  Huang Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Chiou", "title": "Senior VP & Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frazor Titus  Edmondson III, J.D.", "age": 57, "title": "Chief Legal Officer & Joint Corporate Secretary", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 829003, "exercisedValue": 0, "unexercisedValue": 4122300}, {"maxAge": 1, "name": "Dr. Ning  Xu M.D.", "age": 58, "title": "Executive VP & Head of Clinical Operations", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jonathan J.  Wang MBA, Ph.D.", "age": 41, "title": "Chief Business Officer", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Yan DABT, M.D., Ph.D.", "age": 59, "title": "Chief Operating Officer of R&D", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 28.82, "open": 29.1, "dayLow": 28.85, "dayHigh": 29.59, "regularMarketPreviousClose": 28.82, "regularMarketOpen": 29.1, "regularMarketDayLow": 28.85, "regularMarketDayHigh": 29.59, "beta": 1.073, "forwardPE": -15.643244, "volume": 809107, "regularMarketVolume": 809107, "averageVolume": 683292, "averageVolume10days": 789720, "averageDailyVolume10Day": 789720, "marketCap": 2928467712, "fiftyTwoWeekLow": 13.48, "fiftyTwoWeekHigh": 31.22, "priceToSalesTrailing12Months": 9.074583, "fiftyDayAverage": 21.9426, "twoHundredDayAverage": 19.564575, "currency": "USD", "enterpriseValue": 27855296512, "profitMargins": -0.92445, "floatShares": 882532091, "sharesOutstanding": 99608800, "sharesShort": 4861245, "sharesShortPriorMonth": 4933445, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.048800003, "heldPercentInsiders": 0.021760002, "heldPercentInstitutions": 0.51028, "shortRatio": 7.37, "shortPercentOfFloat": 0.056199998, "bookValue": 7.175, "priceToBook": 4.0334496, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -298328992, "trailingEps": -3.1, "forwardEps": -1.85, "pegRatio": 0.12, "enterpriseToRevenue": 86.317, "enterpriseToEbitda": -81.07, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ZLAB", "underlyingSymbol": "ZLAB", "shortName": "Zai Lab Limited", "longName": "Zai Lab Limited", "firstTradeDateEpochUtc": 1505914200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8abb8ada-ed23-324a-aac0-9a720ac3e08a", "gmtOffSetMilliseconds": -14400000, "currentPrice": 28.94, "targetHighPrice": 66.0, "targetLowPrice": 25.0, "targetMeanPrice": 49.29, "targetMedianPrice": 50.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 630048000, "totalCashPerShare": 0.642, "ebitda": -343593984, "totalDebt": 83682000, "quickRatio": 2.812, "currentRatio": 3.456, "totalRevenue": 322711008, "debtToEquity": 11.884, "revenuePerShare": 3.32, "returnOnAssets": -0.21129999, "returnOnEquity": -0.3646, "freeCashflow": -193328624, "operatingCashflow": -202468000, "revenueGrowth": 0.459, "grossMargins": -0.19384001, "ebitdaMargins": -1.06471, "operatingMargins": -0.75683, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-24"}]